- Home
- ANGH vs THAR Comparison
ANGH vs THAR Comparison
Compare ANGH & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- THAR
- Stock Information
- Founded
- ANGH 2012
- THAR 2017
- Country
- ANGH United Arab Emirates
- THAR United States
- Employees
- ANGH N/A
- THAR N/A
- Industry
- ANGH Telecommunications Equipment
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- THAR Health Care
- Exchange
- ANGH Nasdaq
- THAR Nasdaq
- Market Cap
- ANGH 19.1M
- THAR 22.8M
- IPO Year
- ANGH N/A
- THAR 2022
- Fundamental
- Price
- ANGH $2.95
- THAR $3.05
- Analyst Decision
- ANGH
- THAR Strong Buy
- Analyst Count
- ANGH 0
- THAR 1
- Target Price
- ANGH N/A
- THAR $17.00
- AVG Volume (30 Days)
- ANGH 7.2K
- THAR 276.0K
- Earning Date
- ANGH 11-07-2025
- THAR 11-07-2025
- Dividend Yield
- ANGH N/A
- THAR N/A
- EPS Growth
- ANGH N/A
- THAR N/A
- EPS
- ANGH N/A
- THAR N/A
- Revenue
- ANGH $78,093,405.00
- THAR N/A
- Revenue This Year
- ANGH N/A
- THAR N/A
- Revenue Next Year
- ANGH N/A
- THAR N/A
- P/E Ratio
- ANGH N/A
- THAR N/A
- Revenue Growth
- ANGH 88.72
- THAR N/A
- 52 Week Low
- ANGH $2.53
- THAR $0.95
- 52 Week High
- ANGH $9.40
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- ANGH 51.60
- THAR 50.42
- Support Level
- ANGH $2.53
- THAR $2.68
- Resistance Level
- ANGH $2.94
- THAR $3.21
- Average True Range (ATR)
- ANGH 0.10
- THAR 0.26
- MACD
- ANGH 0.00
- THAR 0.01
- Stochastic Oscillator
- ANGH 89.33
- THAR 44.05
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.